Gold nanoparticle–choline complexes can block nicotinic acetylcholine receptors

Abstract: We identified a novel class of direct ion-channel blockers of ligand-gated ion channels called the gold nanoparticle–choline complex. Negatively charged gold nanoparticles (1.4 nm) block ion pores by binding to the sulfur group of the cysteine loop of nicotinic acetylcholine receptors (nAChRs), and currents evoked by acetylcholine (Ach) can break these bonds. The current evoked by Ach in nAChRs was blocked directly in ion pores by the gold nanoparticle–choline complex. In adrenal-gland perfusion studies, the complex also blocked nAChRs by diminishing catecholamine release by about 75%. An in vivo study showed muscle relaxation in rats after injection of the complex. These results will foster the application of gold nanoparticles as a direct ion-channel blocker.

Keywords: negatively charged gold nanoparticle, choline, gold–sulfur bond, nicotinic acetylcholine receptor, direct ion-channel blocker

Introduction

Nicotinic acetylcholine receptors are ion receptors that control the ion pathways of cell membranes through ligands (ie, ligand-gated ion channels). At high concentrations, above 100 µM, choline can block muscular nAChRs at the selectivity filter, suggesting regulation of the activation gate.1 An nAChR has five subunits and a binding site for Ach, which is located outside the α subunits in the muscular receptors. When Ach binds to the binding site, the ion path remains open, allowing positive ions to enter the cell. This process leads to structural change in each subunit.2

Recently, gold nanoparticles were applied to cancer detection by adding nanoparticle-bound antibodies to cells, and they have been used in molecular imaging because of their unique mechanical, chemical, and electrical properties. The numerous properties of 1.4 nm negatively charged gold nanoparticles make them attractive candidates as ion-channel blockers, especially to cysteine loop superfamly receptors: small size to enter the extracellular vestibule, stability due to conjugation between the gold nanoparticle and the adjacent sulfur group, less toxicity than fullerenes and other metallic nanoparticles, and ease of separation from weak ionic bonds.

Negatively charged nanoparticles can block the ion pores of ligand-gated ion channels when they are introduced into the pores via other molecules.3 Choline (0.55 nm) is a good candidate for introducing gold nanoparticles into the extracellular vestibule (3 nm diameter) of the receptors (Figure 1).1

The identification of new classes of molecules to target ion pores is of significant interest in drug discovery because if these molecules can directly block ion pores, the
blocking effects of the channel are increased and no other
channels are blocked. Direct blocking of the ion pores of
nAChRs could be applied clinically as a potent intravenous
anesthetic therapy with fewer side effects. Therefore, we
explored the possibility of using a novel material such as
gold nanoparticles as a direct ion-channel blocker.

**Material and methods**

Local ethical approval was received for conducting the
study.

**Materials**

The 1.4 nm negatively charged gold nanoparticles were
purchased from Nanoprobes, Inc (New York, NY). The ionic
bond was induced by vortexing 1 mM positively charged
choline and 15 nM negatively charged gold nanoparticles
for about 15 min followed by mixing with a pipette for
15 min. The negatively charged CoO⁻ particles coated on
the thin film of nanoparticles bound to the N⁺ group of the
choline molecule. Choline hydroxide solution was obtained
from Sigma-Aldrich (St. Louis, MO). The PC 12 cell line
was obtained from the American Type Culture Collection
CRL-1721 (Manassas, VA).

**Electrophysiology**

We plated the PC 12 cells on collagen and poly-L-lysine-coated
coverslips. The cells were cultured on these coverslips for
2–4 days before use. Membrane currents were recorded by
using the whole cell voltage clamp method.¹ The cells on
coverslips were placed in a recording bath with an
approximate volume of 1.5 mL and continuously perfused
at the rate of 1–2 mL min⁻¹ with a standard external solution
containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂,
1.0 mM MgCl₂, 10 mM HEPES, and 11.1 mM glucose
(titrated to pH 7.4 with NaOH). The heat-polished patch
pipettes had a tip resistance of 3–7 M when filled with an
intracellular solution containing 150 mM CsCl, 10 mM
HEPES, 5 mM ethylene glycol tetraacetic acid (EGTA),
and 2 mM adenosine triphosphate (ATP)-Mg (titrated to pH
7.3 with CsOH). The cells were voltage-clamped at −60 mV
with a patch clamp amplifier, Flyscreen 8500 Patch Clamp
Robot (Heka Elektronik, Lambrecht/Pfalz, Germany). Whole
cell currents were filtered at 0.2 kHz with a Bessel filter
and digitized at 1 kHz. Data were stored and analyzed on
a microcomputer by using pCLAMP software (Axon CNS
Molecular Devices, Silicon Valley, CA). All experiments
were performed at room temperature (22–25°C).

**In vitro tissue (adrenal gland) study**

Male Sprague–Dawley (SD) rats, weighing 200–300 g,
were anesthetized with thiopental sodium (50 mg kg⁻¹) by
intrapitoneal injection. The adrenal glands of each rat were
isolated by using the Wakade method.⁵ The abdomen was
opened with a midline incision, and the left adrenal gland
and surrounding area were exposed by using three-hook
retractors. The stomach, intestine, and portions of the liver
were not removed but pushed over to the right side and
covered with saline-soaked gauge pads. Urine was removed
from the bladder to obtain enough working space for tying
the blood vessels and cannulating. A cannula, used for perfusion
of the adrenal gland, was inserted into the distal end of the
renal vein after all branches of the adrenal vein (if any),

**Figure 1** Gold nanoparticles in the extracellular vestibule of receptors.
vena cava, and aorta were ligated. Heparin (400 IU mL⁻¹) was injected into the vena cava to prevent blood coagulation before the vessels were ligated and cannulated. A small slit was made in the adrenal cortex opposite the entrance of the adrenal vein. Perfusion of the gland was started, ensuring that no leakage occurred and that the perfusion fluid escaped only from the slit in the adrenal cortex. Then, the adrenal gland, along with the ligated blood vessels and the cannula, was carefully removed and placed on the platform of a leucite chamber. The chamber was continuously circulated with water heated at 37°C ± 1°C.

The adrenal glands were perfused by using an Isco Wiz peristaltic pump (Teledyne Isco, Lincoln, NE) at the rate of 0.32 mL min⁻¹. The perfusion was carried out with Krebs bicarbonate solution of the following composition: 118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.18 mM MgCl₂, 25 mM NaHCO₃, 1.2 mM KH₂PO₄, and 11.7 mM glucose. The solution was constantly bubbled with 95% O₂ and 5% CO₂, and the final pH of the solution was maintained at 7.4–7.5. The solution contained disodium ethylenediaminetetraacetic acid (EDTA, 10 µg mL⁻¹) and ascorbic acid (100 µg mL⁻¹) to prevent oxidation of the catecholamines (CAs).

In addition to a single injection of ACh (1.2 ± 0.1 µg in a 0.05 mL buffer solution at room temperature for 4 min), the agonistic effect of ACh was confirmed in a control experiment with 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP). The gold nanoparticle–choline complex was readministered 4 min after the initial injection, and the change in CA secretion was measured. Prior to stimulation with various secretagogues, the perfusate was collected for 4 min to determine the spontaneous secretion of CAs (background sample). Immediately after collection of the background sample, collection of the perfusates was continued in another tube as soon as the perfusion medium containing the stimulatory agent reached the adrenal gland. Perfusate from the stimulated sample was collected from 4 min to 8 min after the injection. The amount secreted in the background sample was subtracted from that secreted in the stimulated sample to obtain the net secretion value of CAs. The buffer solution was perfused every 2 s. Finally, 10 µM DMPP stimulation was performed for 2 s as a reverse condition. The CA content of the perfusate was measured directly by the fluorometric method without the intermediate purification alumina by using a fluorospectrophotometer (Kontron Co, Milano, Italy).

A volume of 0.2 mL of the perfusate was used for the reaction. The CA content in the perfusate of the stimulated glands was high enough to obtain readings several folds greater than the reading of the control samples (unstimulated). The results for the sample blanks were lowest for perfusates of the stimulated and unstimulated samples. The CA content in the perfusate is expressed in terms of norepinephrine (base) equivalents. The data are the average of five replicates.

**In vivo electroencephalography**

Six adult SD rats grouped in threes (300–350 g, 10 weeks old) were deeply anesthetized with ketamine, xylazine, and acepromazine (65:5:1 mg kg⁻¹ in 2 mL kg⁻¹ initial dose and 1 mL kg⁻¹ booster, as needed, by intraperitoneal injection) for implantation of a metal U-frame. The frame stabilized the head with screws to a sliding carriage adapter within the stereotaxic frame; electrodes for electroencephalography (EEG) were also implanted. For the EEG, small screws were threaded into the skull to contact the dura over the anteromedial prefrontal, retrosplenial (also the posterior cingulate), parietal, and occipital cortices of each side and over the olfactory bulb on one side. One screw was inserted in the frontal bone between the frontal lobes and the olfactory bulbs to serve as a reference. After the animals recovered from surgery, they were allowed to accustom to the head fixation for seven days. Within the plexiglas box, the animals were provided with warm blankets (24°C). The head fixation prevented them from twisting, but they were otherwise able to move their bodies and limbs relatively freely.

**In vivo telemetry**

In the in vivo experiments, we monitored activity using the Data Systems International (DSI) telemetry system™ after intravenously injecting the rats with the complex. The SD rats (300–350 g) with the implantable transmitters were carefully monitored by recording in the cages. We measured the biopotential activity of the skeletal muscles in the extremities via a sensor implanted in the rat’s abdomen.

**Results**

**Electrophysiology**

The PC 12 cloned cell line was derived from a CA-secreting tumor of rat adrenal medulla, which has sympathetic neurons. When the cells were voltage-clamped at −60 mV, bath application of 30 µM ACh produced an inward current. Next, when treated with the 1 mM choline and 15 nM nanoparticle complex (Figure 2), the peak amplitude was inhibited to near the baseline. This inhibition was reversible and was easily eliminated by a 40-min washout. A solution of 1 mM choline and 30 nM nanoparticles inhibited the peak amplitude completely, probably because of complete occlusion of the ion pores: this effect was not eliminated by washout.
In vitro tissue study
The secretagogues were administered at 15-min intervals. Gold nanoparticle–choline complexes were detected for 60 min after the establishment of control release. When the cells were treated with the 1 mM choline and 15 nM nanoparticle complex, we confirmed that the CA secretion evoked by ACh and stimulation of the selective neuronal-type AChR agonist, DMPP, were reduced by about 75% after 60 min. When ACh was readministered after about 1.5 hr, we confirmed that reversal was achieved (Figure 3).

To exclude mass effects, we also included an intravenous injection of an organic cation substitute, which comprised a 450 µL solution containing 1 mM ACh and 15 nM gold nanoparticles. Injection of this solution caused lacrimation and urination in the rats, which are agonistic effects of the AChR and were not due to the receptor blockage.

In vivo EEG
The rats were injected with a 450 µL solution containing 1 mM choline and 15 nM nanoparticles, a 900 µL solution containing 1 mM choline and 15 nM nanoparticles, or a 450 µL solution containing 1 mM choline and 30 nM nanoparticles. On injection of the 450 µL solution with 1 mM choline and 15 nM nanoparticles, the EEG patterns did not change with muscle paralysis 1 hr later. The rats were deeply anesthetized with loss of consciousness and pain, and they showed no reflexes for another 1 hr. During this deep anesthesia, there were no changes in vital signs such as blood pressure and heart rate, which were monitored by catheters in the femoral arteries. Injection of the 900 µL solution with 1 mM choline and 15 nM nanoparticles caused immediate muscle relaxation. Injection of the 450 µL solution with 1 mM choline and 30 nM nanoparticles caused immediate death. Injection of 15 nM gold nanoparticles only or 1 mM choline only resulted in no definite change on EEG.

In vivo telemetry
The animals showed intermittent activity after injection of the 450 µL solution with 1 mM choline and 15 nM nanoparticles. In contrast, we detected no activity after injection of the
900 µL solution with 1 mM choline and 15 nM nanoparticles. The rats injected with the 450 µL solution with 1 mM choline and 30 nM nanoparticles died immediately (Figure 4). Injection of 15 nM gold nanoparticles only or 1 mM choline only had no definite effect.

**Discussion**

Choline binds to the pore domain with an affinity that does not differ much from the affinity of the transmitter-binding sites for these molecules. The pore-blocking site for choline is the selectivity filter and can hamper the closure of the activation gate. Gold nanoparticles (1.4 nM) constitute a new class of ion-channel inhibitors that directly block ligand-gated nAChRs when accompanied into the ion pore by choline. Blocking of nAChRs caused by the gold nanoparticle–choline complex likely occurs in the ascending reticular activating system of the brainstem, skeletal muscles, and adrenal...
Figure 4 After injection with choline and nanoparticle solution.

**Normal SD rat (300–350 g)**

<table>
<thead>
<tr>
<th>Time (hour)</th>
<th>Mean arterial pressure (mmHg)</th>
<th>Corneal reflex</th>
<th>Pain response (tail pinch)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>125</td>
<td>(+)</td>
<td>(+)</td>
</tr>
</tbody>
</table>

**450 µL injection containing 1 mM choice and 15 nM nanoparticle**

<table>
<thead>
<tr>
<th>Time (hour)</th>
<th>Mean arterial pressure (mmHg)</th>
<th>Pain response (tail pinch)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>125</td>
<td>(-)</td>
</tr>
</tbody>
</table>

**900 µL injection containing 1 mM choline and 15 nM nanoparticle**

<table>
<thead>
<tr>
<th>Time (hour)</th>
<th>Mean arterial pressure (mmHg)</th>
<th>Pain response (tail pinch)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>125</td>
<td>(-)</td>
</tr>
</tbody>
</table>
Gold nanoparticles as a direct ion-channel blocker

Dovepress

The mechanism appears to be governed by the formation and dissolution of gold–sulfur bonds between the gold nanoparticles and the cysteine loop of the nAChRs (Supplement 1). This direct blocking agent has a high therapeutic potential for muscle relaxation in vivo (Supplement 2), and does not cause the blocking effects of any other receptors with similar chemical structures (to view the supplements please click the links above or visit http://dovepress.com/submission_video_10466.php). This study shows that the gold nanoparticle–choline complex has characteristics of direct ion-pore blockers. In our in vivo study, we found that blood pressure was not lowered after injection of the complex, contrary to conventional inhalational or intravenous anesthesia, which suppresses myocardial contractility.

Conclusion

In conclusion, gold nanoparticles block the function of the channel probably by fitting into the pore and either hindering ion movement or preventing further conformational changes. Here, we have taken a further step in the effort to use gold nanoparticles for therapeutic purposes.

Disclosures

The authors report no conflicts of interest in this work.

References

1. Purohit Y, Grosman C. Block of muscle nicotinic receptors by choline suggests that the activation and desensitization gates act as distinct molecular entities. J Gen Physiol. 2006;127:703–717.